TISSUEBLUE Drug Patent Profile
✉ Email this page to a colleague
When do Tissueblue patents expire, and what generic alternatives are available?
Tissueblue is a drug marketed by Dutch Ophthalmic and is included in one NDA.
The generic ingredient in TISSUEBLUE is brilliant blue g. One supplier is listed for this compound. Additional details are available on the brilliant blue g profile page.
Summary for TISSUEBLUE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 29 |
| Patent Applications: | 744 |
| What excipients (inactive ingredients) are in TISSUEBLUE? | TISSUEBLUE excipients list |
| DailyMed Link: | TISSUEBLUE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TISSUEBLUE
Generic Entry Date for TISSUEBLUE*:
Constraining patent/regulatory exclusivity:
INDICATED TO SELECTIVELY STAIN THE INTERNAL LIMITING MEMBRANE (ILM) NDA:
Dosage:
SOLUTION;OPHTHALMIC |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for TISSUEBLUE
| Drug Class | Disclosing Agent |
| Mechanism of Action | Dyes |
US Patents and Regulatory Information for TISSUEBLUE
TISSUEBLUE is protected by zero US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of TISSUEBLUE is ⤷ Try a Trial.
This potential generic entry date is based on INDICATED TO SELECTIVELY STAIN THE INTERNAL LIMITING MEMBRANE (ILM).
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
FDA Regulatory Exclusivity protecting TISSUEBLUE
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
INDICATED TO SELECTIVELY STAIN THE INTERNAL LIMITING MEMBRANE (ILM)
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dutch Ophthalmic | TISSUEBLUE | brilliant blue g | SOLUTION;OPHTHALMIC | 209569-001 | Dec 20, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Dutch Ophthalmic | TISSUEBLUE | brilliant blue g | SOLUTION;OPHTHALMIC | 209569-001 | Dec 20, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
